Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celyad OncologyCLYYF +40.00%28 EV-to-OCF is -1.40 as of Aug. 11, 2026. GuruFocus rates CLYYF with a GF Score™ of 28/100 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,406 Biotechnology companies, Celyad Oncology ranks worse than 61.31% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Celyad Oncology's Enterprise Value is $11.27 Mil.
Celyad Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.02 Mil. Therefore, Celyad Oncology's EV-to-OCF for today is -1.40.
The historical rank and industry rank for Celyad Oncology's EV-to-OCF or its related term are showing as below:
CLYYF'
s EV-to-OCF Range Over the Past 10 Years
Min: -16.27 Med: -1.53 Max: 1.62
Current: -1.41
During the past 13 years, the highest EV-to-OCF of Celyad Oncology was 1.62. The lowest was -16.27. And the median was -1.53.
CLYYF's EV-to-OCF is ranked worse than 61.31% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs CLYYF: -1.41
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Celyad Oncology's PE Ratio (TTM) for today is calculated as:
Celyad Oncology's share price for today is $0.28.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Celyad Oncology EV-to-OCF Related Terms
Celyad Oncology EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celyad Oncology's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's EV-to-OCF falls into.
Celyad Oncology's current Enterprise Value is $11.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a EV-to-OCF of -1.40 as of Aug. 11, 2026. According to the industry distribution chart, Celyad Oncology ranks #862 out of 1406 companies in the Biotechnology industry, placing it in the top 61.3%.
Is Celyad Oncology's EV-to-OCF too high?
Celyad Oncology's current EV-to-OCF is -1.40. Based on the distribution chart, Celyad Oncology ranks #862 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #862 out of 1406 companies for EV-to-OCF. This places Celyad Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Celyad Oncology's current EV-to-OCF is -1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The current EV-to-OCF is -1.40. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current EV-to-OCF is -1.40 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
